2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Breast Neoplasms
10
Stomach Neoplasms
6
Colorectal Neoplasms
6
Biliary Tract Neoplasms
4
Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Gallbladder Neoplasms
2
Cholangiocarcinoma
2
Adenocarcinoma Of Esophagus
2
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Muscle Invasive Bladder Cancer (MIBC)
1
Metastatic HER2-positive Breast Cancer
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
HER2-expressing Cancers
1
HER2-Positive Advanced Biliary Tract Cancer
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Advanced Malignancies
1
Interventions
Cisplatin
258
Radiotherapy
193
Cetuximab
151
pembrolizumab
123
Docetaxel
97
Fluorouracil
92
Carboplatin
80
Paclitaxel
78
Radiotherapy, Intensity-Modulated
72
Surveys and Questionnaires
46
Nivolumab
42
Drug Therapy
34
Radiation
33
Blood Specimen Collection
27
Erlotinib Hydrochloride
26
Gemcitabine
25
Immunohistochemistry
22
Gefitinib
22
Cyclophosphamide
22
Surgical Procedures, Operative
21
Standard of Care
20
durvalumab
19
Pemetrexed
19
Magnetic Resonance Spectroscopy
19
Radiosurgery
17
Capecitabine
17
Chemotherapy, Adjuvant
16
Celecoxib
16
Biopsy
16
atezolizumab
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
zanidatamab
×
Clear all
NCT07192068
2025-12-19
AcSé HER2
UNICANCER
Phase 2
Recruiting
105 enrolled